The NPM1 mutation, typically a favorable prognostic marker in newly diagnosed AML, loses this advantage in the relapsed/refractory setting. Survival for relapsed NPM1 patients becomes as poor as for those without the mutation, justifying aggressive targeted therapy with menin inhibitors.

A major limitation of menin inhibitor monotherapy is acquired resistance. Up to 39% of patients on revumenib develop mutations in the menin (MEN1) gene. These mutations prevent the drug from binding to its target, leading to rapid relapse and highlighting the need for combination therapies or next-generation agents.

Despite clinical efficacy, menin inhibitor monotherapy provides a relatively short duration of response (4-6 months) in the relapsed/refractory setting. Their main clinical benefit is achieving a deep enough remission to allow patients to proceed to a potentially curative allogeneic stem cell transplant.

Subgroup analyses of menin inhibitor trials reveal a key difference for treatment sequencing. Patients with prior venetoclax exposure showed lower response rates to Revumenitib. In contrast, early data for Ziftomenib suggests prior venetoclax use did not negatively impact its efficacy.

Combinations of menin inhibitors with standard chemotherapy are achieving impressively high remission rates (e.g., 89% composite remission) in newly diagnosed KMT2A-rearranged AML. This is a significant development, as this genetic subtype has historically been very challenging to treat effectively.

When an AML patient presents with multiple targetable mutations (FLT3, NPM1, IDH), clinicians follow a treatment hierarchy. FLT3-targeted therapy is typically the first choice due to its aggressive phenotype. Menin inhibitors for NPM1 are next, followed by IDH inhibitors, guiding treatment decisions in complex cases.

While adding a menin inhibitor to the azacitidine/venetoclax doublet for older/unfit AML patients increases response rates, it leaves little reserve for marrow function. This can lead to increased risk of early, fatal complications like infection or bleeding, requiring careful dose management.

Combining menin inhibitors with intensive chemotherapy can decrease the risk of differentiation syndrome, a severe side effect. The chemotherapy debulks the tumor, reducing the number of malignant cells available to cause this inflammatory reaction when they differentiate, improving tolerability.

When menin inhibitors are combined with a chemotherapy backbone like induction or Aza/Ven for newly diagnosed AML, the risk of differentiation syndrome (DS) is significantly lower than when they are used as monotherapy in the relapsed setting.